InnoCare Pharma Ltd
SSE:688428

Watchlist Manager
InnoCare Pharma Ltd Logo
InnoCare Pharma Ltd
SSE:688428
Watchlist
Price: 23.83 CNY -0.87%
Market Cap: 20.1B CNY

Wall Street
Price Targets

Price Targets Summary
InnoCare Pharma Ltd

Wall Street analysts forecast InnoCare Pharma Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 39.54 CNY with a low forecast of 34.34 CNY and a high forecast of 49.64 CNY.

Lowest
Price Target
34.34 CNY
44% Upside
Average
Price Target
39.54 CNY
66% Upside
Highest
Price Target
49.64 CNY
108% Upside
InnoCare Pharma Ltd Competitors:
Price Targets
LGND
Ligand Pharmaceuticals Inc
32% Upside
ADAG
Adagene Inc
433% Upside
REGN
Regeneron Pharmaceuticals Inc
7% Upside
BONEX
Bonesupport Holding AB
116% Upside
VCEL
Vericel Corp
52% Upside
KURA
Kura Oncology Inc
222% Upside
096530
Seegene Inc
71% Upside
DVAX
Dynavax Technologies Corp
95% Upside

Revenue
Forecast

Revenue Estimate
InnoCare Pharma Ltd

For the last 3 years the compound annual growth rate for InnoCare Pharma Ltd's revenue is -1%. The projected CAGR for the next 3 years is 47%.

-1%
Past Growth
47%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
InnoCare Pharma Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Net Income
Forecast

Net Income Estimate
InnoCare Pharma Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is InnoCare Pharma Ltd's stock price target?
Price Target
39.54 CNY

According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 39.54 CNY with a low forecast of 34.34 CNY and a high forecast of 49.64 CNY.

What is InnoCare Pharma Ltd's Revenue forecast?
Projected CAGR
47%

For the last 3 years the compound annual growth rate for InnoCare Pharma Ltd's revenue is -1%. The projected CAGR for the next 3 years is 47%.

Back to Top